Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title
24 Apr 2008 Biolex Therapeutics Researchers Present Locteron® Phase 2a Hepatitis C Trial Results at EASL Conference
24 Apr 2008 Jerini Receives Positive CHMP Opinion Recommending European Approval for Icatibant in the Treatment of HAE; FDA Issues Not Approvable Letter
23 Apr 2008 Cytheris Announces New Phase I Study of Interleukin-7 As Immunotherapy In Treatment of Bone Marrow or Peripheral Blood Stem Cell Transplant Patients
23 Apr 2008 Stem Cell Therapeutics Corp. Receives "May Proceed" From FDA for Its Phase IIb Clinical Stroke Trial and IND
22 Apr 2008 Spectrum Pharmaceuticals Provides an Update on Ozarelix in BPH
22 Apr 2008 Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
22 Apr 2008 Eurand Announces EUR-1008 (Zentase) Eligibility for European Centralized Review
21 Apr 2008 Savient Provides Update On Puricase(R) (pegloticase) Biologics License Application
21 Apr 2008 Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
21 Apr 2008 Genzyme Provides Update on Myozyme(R) Manufacturing
18 Apr 2008 Aida Announces New Anti-Cancer Drug Under Development
18 Apr 2008 Lipid Sciences Presents HDL Mimetic Peptide Data at Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference
17 Apr 2008 12 Month Analysis of Juvista Clinical Trials 0050 and 0036
16 Apr 2008 Zelos Therapeutics and Aegis Therapeutics Announce Collaboration for Intranasal Delivery of Zelos’ ZT-031
16 Apr 2008 Teva Seeks Approval for the Extension of its Indication to Include the Treatment of Patients with a First Clinical Event Suggestive of MS
14 Apr 2008 Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
14 Apr 2008 TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanismof-Action at AACR Annual Meeting
14 Apr 2008 Debiopharm and Airmid Sign Option and License Agreement
10 Apr 2008 Copaxone® Significantly Reduced Annual Relapse Rates And Stabilized Disease Progression In Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment
09 Apr 2008 Pfizer Statement on Exubera Labeling Update in the United States
09 Apr 2008 ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II StudyEvaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
09 Apr 2008 Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
09 Apr 2008 Acorda Therapeutics Signs GGF2 Manufacturing Agreement with CMC ICOS
08 Apr 2008 Protox Initiates Phase 2 BPH Study
08 Apr 2008 WEX Starts Phase III Trial of Tectin(TM) for Cancer Pain
04 Apr 2008 FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
03 Apr 2008 Kamada Announces that it had Succesfully Met the Primary Endpoint in its US Phase III Clinical Trial with Intravenous AAT
02 Apr 2008 Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
01 Apr 2008 ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of
31 Mar 2008 Naglazyme Approved by Japanese Ministry of Health
27 Mar 2008 GTC Biotherapeutics and PharmAthene Extend Agreement for Protexia Program
27 Mar 2008 Positive phase III data unveiled for new GnRH blocker degarelix
27 Mar 2008 OMRIX Biopharmaceuticals Initiates Phase II Clinical Trial for Fibrin Patch Product Candidate
26 Mar 2008 Æterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
26 Mar 2008 SemBioSys initiates toxicology study for safflower-produced insulin
26 Mar 2008 Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
20 Mar 2008 Pharming To Receive Negative Opinion On European Marketing Authorization Application For Rhucin(R)
20 Mar 2008 Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
19 Mar 2008 Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
18 Mar 2008 Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
18 Mar 2008 Biolex Announces Presentation of Preclinical Results for Clot Buster BLX-155 at SIR Annual Scientific Meeting
17 Mar 2008 Ipsen and Medicis Announce Submission of Reloxin BLA in Aesthetics to the FDA
17 Mar 2008 Phylogica and Dynamic Microbials sign anti-bacterial deal
17 Mar 2008 Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
14 Mar 2008 Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
13 Mar 2008 MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
13 Mar 2008 Teva Provides Update On Glatiramer Acetate 40mg For Amyotrophic Lateral Sclerosis (Als)
12 Mar 2008 Unigene Successfully Completes Phase I/II Clinical Study for Oral Calcitonin
11 Mar 2008 Oramed Pharmaceuticals Successfully Completes Phase 1B Clinical Trials of Oral Insulin Capsule
11 Mar 2008 OctoPlus announces publication of Phase I Locteron results in the Journal of Interferon and Cytokine Research
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 151 - 200 of 1301

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Thrombopoiesis-Stimulating Agents (TPO)

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics